Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 + Bevacizumab in Advanced Colorectal Cancer
NCT06092242Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Shandong First Medical University
- Start
- Oct 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in colorectal cancer (CRC), sponsored by Second Affiliated Hospital of Shandong First Medical University. Primary endpoint: Progression Free Survival at 2 years. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06092242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06092242.